此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

长效抗逆转录病毒药物和避孕药在HIV中的药代动力学研究 (PHARAOH)

2026年10月12日 更新者:Rena Patel、University of Alabama at Birmingham

长效抗逆转录病毒药物与避孕选择在HIV预防中的药代动力学研究

This study is being done to understand how long-acting injectable cabotegravir (CAB-LA) used for HIV pre-exposure prophylaxis (PrEP) and hormonal contraceptive methods affect each other when used at the same time. Women who are already using CAB-LA or not using PrEP will choose to join one of several groups based on whether they use injectable contraceptive (IM DMPA), an etonogestrel implant, or no hormonal contraceptive. Participants will have study visits every 4 to 12 weeks for up to 12 or 24 weeks after starting a contraceptive method to collect blood samples and measure levels of CAB-LA and hormone concentrations. The study will compare these levels to see if taking CAB-LA changes hormone concentrations or if using hormonal contraception changes CAB-LA drug levels. Safety, side effects, satisfaction, and continuation of CAB-LA PrEP and contraceptive methods will also be evaluated.

研究概览

详细说明

Long-acting (LA) HIV pre-exposure prophylaxis (PrEP), such as injectable cabotegravir (CAB-LA), is increasingly available and has the potential to address barriers to adherence seen with daily oral PrEP. LA PrEP regimens can expand options for women and providers to individualize prevention strategies, provide a powerful prevention tool for those facing adherence challenges with oral regimens, and reduce the burden on health systems in resource-limited settings. Another major threat to women's health is unintended pregnancies, and women at risk for HIV face unique challenges in uptake and continuation of long-acting contraceptives. Use of CAB-LA may create synergy with long-acting contraceptives, fostering more consistent uptake and improved health outcomes.

This proposed research study is a prospective, non-randomized, parallel-group pharmacokinetic (PK) study among a sentinel cohort of five distinct groups of AGYW, and will leverage existing control groups. The study will be conducted in Botswana.

This study will generate critical data to guide future implementation studies integrating CAB-LA PrEP and contraceptive services. Providing an array of prevention and reproductive health options has the potential to empower women to make informed decisions, improve adherence and continuation, and inform real-world considerations for co-delivery or future co-formulations of PrEP and contraceptives.

Our central hypotheses are the following:

  • CAB-LA will not adversely influence hormonal contraceptive concentrations;
  • Hormonal contraceptive method use will not adversely modify CAB-LA concentrations below therapeutically relevant plasma concentrations.

Primary Objectives:

  • To evaluate any associations between CAB-LA exposure and hormonal contraceptive use in the three groups of IM DMPA, ETG implant, and non-hormonal method users by generating geometric mean hormone concentrations throughout 12 weeks for IM DMPA or 24 weeks for ETG implant and no hormonal method groups (Aim 1a)
  • To evaluate any associations between hormonal contraceptive exposure and CAB-LA use by generating geometric mean trough CAB-LA concentrations measured immediately prior to dosing of next CAB-LA (Aim 1b)

Exploratory Objectives

  • To assess safety, including side effects, satisfaction, and continuation rates of both LA ART/PrEP and hormonal contraceptive method (Aim 2a)
  • To qualitatively explore decision-making around PrEP and contraceptive method options, study experiences with use of/switch to CAB-LA and contraceptive method (Aim 2b)

研究类型

观察性的

注册 (估计的)

105

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Gaborone
      • Bontleng、Gaborone、博茨瓦纳
        • 招聘中
        • Princess Marina Hospital
        • 接触:
          • Chelsea Morroni, MBChB, DFSRH, DTMH, MPhil, MPH
          • 电话号码:+267 765 24112
          • 邮箱:cmorroni@ed.ac.uk
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

女性

取样方法

非概率样本

研究人群

Adult females aged 18 years or older who are HIV-seronegative

描述

Parent Tshireletso Study Inclusion Criteria:

  1. Female 18 years of age or older and willing and able to provide an informed consent
  2. < 14 days after delivery (calendar day of birth = day 0)
  3. Negative HIV screening test (conducted at the time of enrolment)
  4. Female <30 years old or has had < 3 prior pregnancies (Gravida 1, 2, or 3 including this pregnancy)
  5. Plan to stay and receive postpartum and pediatric care in the Gaborone or Molepolole region for 24 months

Parent Tshireletso Study Exclusion Criteria

  1. Receiving carbamazepine, phenobarbital, phenytoin, oxycarbazepine, rifampin, rifabutin, rifapentine, systemic dexamethasone (>1 dose oral/IV), or St. John's wort
  2. Suspected to have, recently diagnosed with, or on treatment for TB (due to interaction with rifampicin)
  3. Previous hypersensitivity reaction to CAB or other INSTI
  4. Unstable medical or psychiatric condition making it unlikely they will be able to adhere to injections every 2 months
  5. Plan for pediatric and post-partum care outside the government system (private clinics)
  6. Inflammatory skin condition that compromises the safety of the intramuscular injection
  7. Weight <35kg

Parent Doris Duke Study Inclusion Criteria Post-partum females included;

  1. if HIV-uninfected or unknown HIV status, willing to be tested for HIV
  2. if HIV-infected, documented to be on DTG as part of an antiretroviral treatment regimen
  3. maternal age >18 years,
  4. ability to speak English or Setswana
  5. intend to be available for follow up in Molepolole, Gaborone or Mochudi for 18 months post-delivery
  6. have access to a cell phone (including phone of friend or relative)

Parent Doris Duke Study Exclusion Criteria Post-partum females excluded if

  1. did not attend antenatal care or were not included in Tsepamo surveillance
  2. maternal age <18,
  3. females who do not speak English or Setswana,
  4. unable or unwilling to give consent
  5. will not be able to attend follow up at a study site
  6. do not have access to any cell phone for follow up calls

Additional Inclusion Criteria for this PK Study

  1. For DMPA and ETG implant groups, intends to initiate or continue use of DMPA or ETG implant for at least another three or six months, respectively,
  2. For the CAB-LA groups, have received at least three consecutive CAB injections on time, including the one administered concurrently while starting a contraceptive method,
  3. Willing to undergo phlebotomy every 4 weeks for the duration of the sub-study period Additional Exclusion Criteria for this PK Study

1) Use or anticipated use of nicotine-containing products (e.g., cigarettes or hookahs) known to interact with CAB-LA for the duration of the sub-study period 2) Use within the previous 90 days, current use, or planned future concomitant use of other hormonal contraceptives, including oral contraceptive methods 3) BMI≥35 4) Has any of the following laboratory abnormalities within the last year:

  1. Serum ALT>5x ULN at the time of screening,
  2. Serum creatinine >2.5x ULN at the time of screening. 5) Has any other condition that, in the opinion of the sub-study PI/designee, would preclude informed consent, make study participation unsafe, or complicate interpretation of study outcome 6) HIV infected females on the Doris Duke parent study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Group 1: CAB-LA + IM DMPA

Injectable cabotegravir 600mg + intramuscular depo-medroxyprogesterone acetate 150mg (IM DMPA)

Injectable cabotegravir 600 mg administered as long-acting HIV pre-exposure prophylaxis (PrEP).

Group 2: CAB-LA + ETG implant

Injectable cabotegravir 600mg + etonogestrel (ETG) implant 68mg

Injectable cabotegravir 600 mg administered as long-acting HIV pre-exposure prophylaxis (PrEP).

Group 3: CAB-LA + no hormonal method

Injectable cabotegravir 600mg + no hormonal method

Injectable cabotegravir 600 mg administered as long-acting HIV pre-exposure prophylaxis (PrEP).

Group 4: No PrEP + IM DMPA

No PrEP + intramuscular depot medroxyprogesterone acetate (IM DMPA) 150mg

No HIV pre-exposure prophylaxis administered

Group 5: No PrEP + ETG implant

No PrEP + etonogestrel (ETG) implant 68mg

No HIV pre-exposure prophylaxis administered

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
To evaluate any associations between CAB-LA exposure and hormonal contraceptive use in the three groups of IM DMPA, ETG implant, and non-hormonal method users by generating geometric mean hormone concentrations (Aim 1a)
大体时间:0, 4, 8, 12 weeks for IM DMPA; 0, 4, 8, 12, 24 weeks for ETG implant and non-hormonal method users

Mean hormone concentrations starting at 0 week (when feasible), 4 weeks, 8 weeks, 12 weeks, and 24 weeks, as applicable to the three contraceptive groups, after contraceptive method initiation and at least after receiving 3rd dose of CAB-LA if in the CAB-LA groups.

0, 4, 8, 12 weeks for IM DMPA; 0, 4, 8, 12, 24 weeks for ETG implant and non-hormonal method users
To evaluate any associations between hormonal contraceptive exposure and CAB-LA use by generating geometric mean trough CAB-LA concentrations measured immediately prior to dosing of next CAB-LA (Aim 1b)
大体时间:Immediately prior to each scheduled CAB-LA injection

Mean trough CAB-LA concentrations prior to next dosing of CAB-LA

Immediately prior to each scheduled CAB-LA injection

次要结果测量

结果测量
措施说明
大体时间
Incidence of adverse events associated with CAB-LA and hormonal contraceptive methods (Aim 2a1)
大体时间:12 and 24 weeks after contraceptive method initiation

Number and proportion of participants experiencing adverse events, graded using the Division of AIDS (DAIDS) Adverse Event Grading Table.

12 and 24 weeks after contraceptive method initiation
Participant satisfaction with CAB-LA and hormonal contraceptive method measured by questionnaire (Aim 2a2)
大体时间:12 and 24 weeks after contraceptive method initiation

Participant-reported satisfaction scores assessed using a questionnaire.

12 and 24 weeks after contraceptive method initiation
Continuation rates of CAB-LA and hormonal contraceptive method (Aim 2a3)
大体时间:12 and 24 weeks after contraceptive method initiation

Proportion of participants continuing use of CAB-LA and the contraceptive method at each time point.

12 and 24 weeks after contraceptive method initiation
Participants' experiences and decision-making regarding CAB-LA and contraceptive method options assessed by semi-structured interviews (Aim 2b)
大体时间:At the end of study participation or up to 12 months after study participation

Qualitative assessment of participants' experiences, preferences, and decision-making processes regarding CAB-LA and contraceptive method use or switching, collected through semi-structured interviews conducted by trained study staff and audio-recorded, transcribed, and analyzed using thematic analysis.

At the end of study participation or up to 12 months after study participation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Rena Patel, MD, MPH, MPhil、University of Alabama at Birmingham
  • 首席研究员:Rebecca Zash、Division of Infectious Disease Beth Israel Deaconess Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年1月24日

初级完成 (估计的)

2026年12月1日

研究完成 (估计的)

2026年12月1日

研究注册日期

首次提交

2026年3月4日

首先提交符合 QC 标准的

2026年3月31日

首次发布 (实际的)

2026年4月8日

研究记录更新

最后更新发布 (实际的)

2026年10月14日

上次提交的符合 QC 标准的更新

2026年10月12日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅